Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.63
CYAN's Cash to Debt is ranked higher than
62% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. CYAN: 0.63 )
CYAN' s 10-Year Cash to Debt Range
Min: 0.06   Max: 8.91
Current: 0.63

0.06
8.91
Equity to Asset 0.68
CYAN's Equity to Asset is ranked higher than
77% of the 754 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. CYAN: 0.68 )
CYAN' s 10-Year Equity to Asset Range
Min: 0.65   Max: 0.92
Current: 0.68

0.65
0.92
F-Score: 4
Z-Score: 2.33
M-Score: -3.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -3.89
CYAN's Operating margin (%) is ranked higher than
56% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.92 vs. CYAN: -3.89 )
CYAN' s 10-Year Operating margin (%) Range
Min: -75.43   Max: 32.46
Current: -3.89

-75.43
32.46
Net-margin (%) -2.17
CYAN's Net-margin (%) is ranked higher than
56% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. CYAN: -2.17 )
CYAN' s 10-Year Net-margin (%) Range
Min: -76.68   Max: 36.84
Current: -2.17

-76.68
36.84
ROE (%) -3.08
CYAN's ROE (%) is ranked higher than
57% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.33 vs. CYAN: -3.08 )
CYAN' s 10-Year ROE (%) Range
Min: -66.15   Max: 27.54
Current: -3.08

-66.15
27.54
ROA (%) -2.15
CYAN's ROA (%) is ranked higher than
57% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. CYAN: -2.15 )
CYAN' s 10-Year ROA (%) Range
Min: -54   Max: 22.08
Current: -2.15

-54
22.08
ROC (Joel Greenblatt) (%) -6.74
CYAN's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.20 vs. CYAN: -6.74 )
CYAN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -70.72   Max: 58.43
Current: -6.74

-70.72
58.43
Revenue Growth (%) 18.00
CYAN's Revenue Growth (%) is ranked higher than
83% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. CYAN: 18.00 )
CYAN' s 10-Year Revenue Growth (%) Range
Min: -9.7   Max: 31
Current: 18

-9.7
31
EBITDA Growth (%) -13.50
CYAN's EBITDA Growth (%) is ranked higher than
57% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. CYAN: -13.50 )
CYAN' s 10-Year EBITDA Growth (%) Range
Min: -26.6   Max: 122.4
Current: -13.5

-26.6
122.4
» CYAN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CYAN Guru Trades in Q3 2013

Jim Simons 80,000 sh (-4.42%)
» More
Q4 2013

CYAN Guru Trades in Q4 2013

Jim Simons 70,400 sh (-12%)
» More
Q1 2014

CYAN Guru Trades in Q1 2014

Jim Simons 68,700 sh (-2.41%)
» More
Q2 2014

CYAN Guru Trades in Q2 2014

Jim Simons 68,700 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CYAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.24
CYAN's P/B is ranked higher than
92% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. CYAN: 1.24 )
CYAN' s 10-Year P/B Range
Min: 0.63   Max: 3.68
Current: 1.24

0.63
3.68
P/S 0.90
CYAN's P/S is ranked higher than
93% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.81 vs. CYAN: 0.90 )
CYAN' s 10-Year P/S Range
Min: 0.42   Max: 3.6
Current: 0.9

0.42
3.6
EV-to-EBIT -24.45
CYAN's EV-to-EBIT is ranked lower than
51% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.17 vs. CYAN: -24.45 )
CYAN' s 10-Year EV-to-EBIT Range
Min: 5.3   Max: 780.4
Current: -24.45

5.3
780.4
Shiller P/E 12.48
CYAN's Shiller P/E is ranked higher than
97% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.28 vs. CYAN: 12.48 )
CYAN' s 10-Year Shiller P/E Range
Min: 11.32   Max: 74.71
Current: 12.48

11.32
74.71
Current Ratio 2.74
CYAN's Current Ratio is ranked higher than
76% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. CYAN: 2.74 )
CYAN' s 10-Year Current Ratio Range
Min: 1.13   Max: 8.33
Current: 2.74

1.13
8.33
Quick Ratio 1.63
CYAN's Quick Ratio is ranked higher than
70% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. CYAN: 1.63 )
CYAN' s 10-Year Quick Ratio Range
Min: 0.54   Max: 7.93
Current: 1.63

0.54
7.93

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.25
CYAN's Price/Tangible Book is ranked higher than
94% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. CYAN: 1.25 )
CYAN' s 10-Year Price/Tangible Book Range
Min: 0.5   Max: 15.84
Current: 1.25

0.5
15.84
Price/DCF (Projected) 1.62
CYAN's Price/DCF (Projected) is ranked higher than
89% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.11 vs. CYAN: 1.62 )
CYAN' s 10-Year Price/DCF (Projected) Range
Min: 0.76   Max: 5.12
Current: 1.62

0.76
5.12
Price/Median PS Value 0.84
CYAN's Price/Median PS Value is ranked higher than
90% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. CYAN: 0.84 )
CYAN' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 23.88
Current: 0.84

0.47
23.88
Earnings Yield (Greenblatt) 0.60
CYAN's Earnings Yield (Greenblatt) is ranked lower than
52% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. CYAN: 0.60 )
CYAN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 18.8
Current: 0.6

0.1
18.8
Forward Rate of Return (Yacktman) 1.14
CYAN's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. CYAN: 1.14 )
CYAN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8   Max: 36.8
Current: 1.14

-8
36.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Cyanotech Corporation was incorporated in 1983. The Company cultivates and produces natural products derived from microalgae for the nutritional supplements market. It currently cultivates two microalgal species from which its two main product lines are derived. Its products include: Hawaiian Spirulina Pacifica - a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids; and Hawaiian BioAstin natural astaxanthin - a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health. It has expanding applications as a human nutraceutical and functional food ingredient. The Company manufactures all of its products in the United States and sells its products worldwide. As the Company's operations are solely related to microalgae-based products, management of the Company considers its operations to be in one industry segment. Several governmental agencies regulate various aspects of its business and its products in the United States, including the Food and Drug Administration, the Federal Trade Commission, the Consumer Product Safety Commission, the State of Hawaii Department of Health, the Department of Agriculture, the Environmental Protection Agency, the United States Postal Service, state attorney general offices and various agencies of the states and localities in which its products are sold.
» More Articles for CYAN

Headlines

Articles On GuruFocus.com
Cyanotech Corp. Reports Operating Results (10-Q) Feb 11 2011 
Cyanotech Corp. Reports Operating Results (10-Q) Nov 10 2010 
Cyanotech Corp. Reports Operating Results (10-K) Jun 24 2010 
Cyanotech Corp. Reports Operating Results (10-Q) Feb 11 2010 
Cyanotech Corp. Reports Operating Results (10-Q) Nov 12 2009 
Cyanotech Corp. Reports Operating Results (10-Q) Aug 13 2009 
Cyanotech Corp. Reports Operating Results (10-Q) Feb 13 2009 

More From Other Websites
CYANOTECH CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Sep 02 2014
CYANOTECH CORP Financials Aug 22 2014
CYANOTECH CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Aug 18 2014
Cyanotech Names Gerry Watts as Chief Operations Officer Aug 18 2014
CYANOTECH CORP Files SEC form 10-Q, Quarterly Report Aug 14 2014
Cyanotech Reports Financial Results for the First Quarter of Fiscal Year 2015 Aug 14 2014
CYANOTECH CORP Files SEC form 10-K, Annual Report Jun 27 2014
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 Jun 27 2014
CYANOTECH CORP Files SEC form 8-K, Other Events Apr 09 2014
CYANOTECH CORP Files SEC form 10-Q/A, Quarterly Report Feb 13 2014
CYANOTECH CORP Files SEC form 10-Q, Quarterly Report Feb 06 2014
Cyanotech Reports Financial Results for the Third Quarter of Fiscal Year 2014 Feb 06 2014
CYANOTECH CORP Files SEC form 10-Q, Quarterly Report Nov 07 2013
Cyanotech Reports Financial Results for the Second Quarter of Fiscal Year 2014 Nov 07 2013
Cyanotech Reports Financial Results for the Second Quarter of Fiscal Year 2014 Nov 07 2013
CYANOTECH CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Sep 04 2013
CYANOTECH CORP Files SEC form 8-K, Other Events Aug 26 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK